Our Pipeline
Using our proprietary drug discovery platform, we are developing a pipeline of first in class precision therapeutics that regulate key muscle proteins to address a broad array of genetically characterized muscle disorders. We have retained global development and commercialization rights to all of our programs. Our current pipeline is summarized below.
PROGRAM
INDICATIONS
Preclinical
Phase 1
Phase 2
Pivotal/
Phase 3
Regulatory Submission
skeletal
cardiovascular
EDG-7500
Undisclosed Sarcomeric Target
HCM
Preclinical
Phase 1
Phase 2
Pivotal/
Phase 3
Regulatory Submission
EDG-003
Undisclosed Target
Cardiometabolic
Preclinical
Phase 1
Phase 2
Pivotal/
Phase 3
Regulatory Submission
Duchenne - Duchenne muscular dystrophy
Becker - Becker muscular dystrophy
HCM - Hypertrophic cardiomyopathy
LGMD - Limb-girdle muscular dystrophy